Stahl SM - Search Results

1

What is the neurobiology of schizophrenia?

Cummings MA, Arias AW, Stahl SM. Cummings MA, et al. Among authors: stahl sm. CNS Spectr. 2024 Oct 30:1-6. doi: 10.1017/S1092852924000518. Online ahead of print. CNS Spectr. 2024. PMID: 39473188 Review.

2

An overview of the pathophysiology of agitation in Alzheimer's dementia with a focus on neurotransmitters and circuits.

Cummings JL, Brubaker M, Selzler KJ, Gonzalez ST, Patel M, Stahl SM. Cummings JL, et al. Among authors: stahl sm. CNS Spectr. 2024 Oct 23:1-10. doi: 10.1017/S1092852924000427. Online ahead of print. CNS Spectr. 2024. PMID: 39438777 Review.

3

Expert consensus statement for telepsychiatry and attention-deficit hyperactivity disorder.

Hong J, Mattingly GW, Carbray JA, Cooper TV, Findling RL, Gignac M, Glaser PE, Lopez FA, Maletic V, McIntyre RS, Robb AS, Singh MK, Stein MA, Stahl SM. Hong J, et al. Among authors: stahl sm. CNS Spectr. 2024 May 20:1-12. doi: 10.1017/S1092852924000208. Online ahead of print. CNS Spectr. 2024. PMID: 38764385 Review.

4

Long-acting injectable antipsychotics: shall the last be first?

Stahl SM. Stahl SM. CNS Spectr. 2014 Feb;19(1):3-5. doi: 10.1017/S1092852913001016. CNS Spectr. 2014. PMID: 24512639

5

Does treating hearing loss prevent or slow the progress of dementia? Hearing is not all in the ears, but who's listening?

Stahl SM. Stahl SM. CNS Spectr. 2017 Jun;22(3):247-250. doi: 10.1017/S1092852917000268. Epub 2017 Apr 5. CNS Spectr. 2017. PMID: 28376938 Review.

6

New hope for Alzheimer's dementia as prospects for disease modification fade: symptomatic treatments for agitation and psychosis.

Stahl SM. Stahl SM. CNS Spectr. 2018 Oct;23(5):291-297. doi: 10.1017/S1092852918001360. CNS Spectr. 2018. PMID: 30382934 Review.

7

Clozapine: is now the time for more clinicians to adopt this orphan?

Stahl SM. Stahl SM. CNS Spectr. 2014 Aug;19(4):279-81. doi: 10.1017/S1092852914000418. CNS Spectr. 2014. PMID: 25267329

8

Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): modifying serotonin's downstream effects on glutamate and GABA (gamma amino butyric acid) release.

Stahl SM. Stahl SM. CNS Spectr. 2015 Aug;20(4):331-6. doi: 10.1017/S1092852915000334. Epub 2015 Jun 11. CNS Spectr. 2015. PMID: 26062900 Review.

9

Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors).

Stahl SM. Stahl SM. CNS Spectr. 2015 Apr;20(2):93-7. doi: 10.1017/S1092852915000139. CNS Spectr. 2015. PMID: 25831967 Review.

10

Dextromethorphan/bupropion: a novel oral NMDA (N-methyl-d-aspartate) receptor antagonist with multimodal activity-Addendum.

Stahl SM. Stahl SM. CNS Spectr. 2020 Dec;25(6):803. doi: 10.1017/S109285291900155X. Epub 2019 Nov 27. CNS Spectr. 2020. PMID: 31771670 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

479 results

Search Page

Filters